Skip to main content
Industry News
F-18 FDG-PET/CT examined in predicting follicular lymphoma progression

Researchers who used F-18 FDG-PET/CT found that people with newly diagnosed follicular lymphoma undergoing rituximab-based chemoimmunotherapy who had positive scans had 39.9 months of median progression-free survival at an interim evaluation point and 14.2 months of median PFS at end-of-induction therapy, compared with 55.5 months of median PFS at interim and 60.5 months of median PFS at EOI among those with negative scans. Multivariate analysis of the findings, which were published in the journal Nuclear Medicine and Molecular Imaging, showed that PET status at EOI alone independently predicted follicular lymphoma progression.

Full Story: